Literature DB >> 35976499

Modulation of TDM-induced granuloma pathology by human lactoferrin: a persistent effect in mice.

Jeffrey K Actor1, Thao K T Nguyen2, Agnieszka Wasik-Smietana3, Marian L Kruzel3.   

Abstract

Lactoferrin (LTF), an iron binding protein, is known to exhibit immune modulatory effects on pulmonary pathology during insult-induced models of primary Mycobacterium tuberculosis (Mtb) infection. The effects of LTF correlate with modulation of the immune related development of the pathology, and altering of the histological nature of the physically compact and dense lung granuloma in mice. Specifically, a recombinant human version of LTF limits immediate progression of granulomatous severity following administration of the Mtb cell wall mycolic acid, trehalose 6,6'-dimycolate (TDM), in part through reduced pro-inflammatory responses known to control these events. This current study investigates a limited course of LTF to modulate not only initiation, but also maintenance and resolution of pathology post development of the granulomatous response in mice. Comparison is made to a fusion of LTF with the Fc domain of IgG2 (FcLTF), which is known to extend LTF half-life in circulation. TDM induced granulomas were examined at extended times post insult (day 7 and 14). Both LTF and the novel FcLTF exerted sustained effects on lung granuloma pathology. Reduction of pulmonary pro-inflammatory cytokines TNF-α and IL-1β occurred, correlating with reduced pathology. Increase in IL-6, known to regulate granuloma maintenance, was also seen with the LTFs. The FcLTF demonstrated greater impact than the recombinant LTF, and was superior in limiting damage to pulmonary tissues while limiting residual inflammatory cytokine production.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Granuloma; Immunopathology; Inflammation; Lactoferrin; Trehalose 6,6′-dimycolate; Tuberculosis

Year:  2022        PMID: 35976499     DOI: 10.1007/s10534-022-00434-0

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   3.378


  60 in total

1.  Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies.

Authors:  Alain Beck; Janice M Reichert
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

2.  Lactoferrin immunomodulation of DTH response in mice.

Authors:  Jeffrey K Actor; Shen-An Hwang; Margaret Olsen; Michal Zimecki; Robert L Hunter; Marian L Kruzel
Journal:  Int Immunopharmacol       Date:  2002-03       Impact factor: 4.932

Review 3.  Lactoferrin as a Human Genome "Guardian"-An Overall Point of View.

Authors:  Iwona Bukowska-Ośko; Dorota Sulejczak; Katarzyna Kaczyńska; Patrycja Kleczkowska; Karol Kramkowski; Marta Popiel; Ewa Wietrak; Paweł Kowalczyk
Journal:  Int J Mol Sci       Date:  2022-05-08       Impact factor: 6.208

Review 4.  Lactoferrin as a natural immune modulator.

Authors:  Jeffrey K Actor; Shen-An Hwang; Marian L Kruzel
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs.

Authors:  Soumya D Chakravarty; Guofeng Zhu; Ming C Tsai; Vellore P Mohan; Simeone Marino; Denise E Kirschner; Luqi Huang; Joanne Flynn; John Chan
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

6.  Lactoferrin Efficiently Counteracts the Inflammation-Induced Changes of the Iron Homeostasis System in Macrophages.

Authors:  Antimo Cutone; Luigi Rosa; Maria Stefania Lepanto; Mellani Jinnett Scotti; Francesca Berlutti; Maria Carmela Bonaccorsi di Patti; Giovanni Musci; Piera Valenti
Journal:  Front Immunol       Date:  2017-06-15       Impact factor: 7.561

Review 7.  Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.

Authors:  Stephen M Carpenter; Lenette L Lu
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

Review 8.  Fc-fusion proteins: new developments and future perspectives.

Authors:  Daniel M Czajkowsky; Jun Hu; Zhifeng Shao; Richard J Pleass
Journal:  EMBO Mol Med       Date:  2012-07-26       Impact factor: 12.137

9.  MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis.

Authors:  Dawn M E Bowdish; Kaori Sakamoto; Mi-Jeong Kim; Mariliis Kroos; Subhankar Mukhopadhyay; Cynthia A Leifer; Karl Tryggvason; Siamon Gordon; David G Russell
Journal:  PLoS Pathog       Date:  2009-06-12       Impact factor: 6.823

Review 10.  Interleukin-10 Family and Tuberculosis: An Old Story Renewed.

Authors:  Abualgasim Elgaili Abdalla; Nzungize Lambert; Xiangke Duan; Jianping Xie
Journal:  Int J Biol Sci       Date:  2016-04-27       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.